Care pathway, site of service, and what is already in the room — pediatric persistent asthma home monitoring

1. Summary

Pediatric persistent asthma is managed under a single, decades-old national framework — the NHLBI/NAEPP Expert Panel Report 3 (EPR-3) — that fixes the pathway's shape: an initial visit that diagnoses, classifies severity, and writes a controller-medication plan and an asthma action plan, followed by scheduled follow-up visits at a cadence set by control status, most often in a pediatric primary care office rather than a specialist's. Self-monitoring — "either symptom or peak flow monitoring" — is already named in the guideline itself as a component of ongoing management. The room this device would enter, however, is one where referral to the specialist tier the guideline calls for at higher treatment steps is uneven: two independent US cohorts each found that only a minority of children with a guideline-level indication for specialist care actually receive it, and PCP referral itself is the identified bottleneck in one of them. A small number of academic pilot programs have already tested wiring a home spirometer into the EHR-based clinical decision support a pediatric practice already runs, and at least one such pilot completed with results.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

The guideline-defined pathway: diagnosis, action plan, and a control-dependent follow-up cadence

The NHLBI/NAEPP EPR-3 "Asthma Care Quick Reference" lays out the pathway as a fixed loop: an initial visit (diagnose asthma, assess severity, initiate medication, develop a written asthma action plan, schedule follow-up) feeding into recurring follow-up visits (assess and monitor control, review the action plan, adjust medication, schedule the next visit) [1][single-source]. Diagnosis itself is age-gated: "In all patients ≥5 years of age, use spirometry to determine that airway obstruction is at least partially reversible" [1][single-source] — below that age, diagnosis rests on history and exam alone, which bounds the population for whom an in-clinic or home spirometer is even diagnostically usable.

Follow-up cadence is explicit and tied to control status, not to a fixed calendar: the guideline directs clinicians to see patients "every 2–6 weeks while gaining control," "every 1–6 months to monitor control," and "every 3 months if step down in therapy is anticipated" [1][single-source]. Once control is reached, the guideline's own recommended action is "Regular follow-up every 1–6 months" [1][single-source] — a wide, control-dependent window that is the direct target a between-visit home monitor is built to fill. Between visits, the guideline additionally directs office-based spirometry "at least every 1–2 years; more frequently for asthma that is not well controlled" [1][single-source], and instructs clinicians to "Teach and reinforce at each visit: Self-monitoring to assess level of asthma control and recognize signs of worsening asthma (either symptom or peak flow monitoring)" [1][single-source] — naming patient-side self-monitoring, without specifying symptom diary versus a peak-flow device, as an already-expected element of ongoing management.

Referral to specialist care is a named guideline step, but a minority actually reach it

EPR-3's stepwise-treatment tables state, per age band, when the pathway hands off from primary care to a specialist: for ages 5–11, "Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3" [1][single-source]; for ages 0–4 and ≥12, the same structure applies at steps 3–4. This makes the specialist tier (allergy/immunology or pediatric pulmonology) a guideline-defined branch of the pathway, not merely an option.

Two independent, non-affiliated US cohorts each measured how often that branch is actually taken, and both found a minority. A retrospective cohort of Maine's 2015–2021 All-Payer Claims Data identified 12,014 children under 18 with a guideline-recognized indication for asthma specialist referral (a complicating comorbidity, higher-level controller medication, ≥3 systemic-corticosteroid courses in a year, or a respiratory hospitalization); only 2,296 (19%) received specialist care within a year of that indication, and the likelihood was significantly lower for children in small towns or isolated rural areas, in lower-Child-Opportunity-Index areas, and farther from a specialist by driving time (adjusted OR 0.62 per additional hour) [2][single-source]. Separately, baseline data from the Rochester, NY "TEAM-UP" trial (325 children ages 4–12 with public-insurance-majority, poorly-controlled asthma) found 37% had ever seen a specialist and 16% had done so in the prior year, and identified the specific bottleneck: "only 23% of children were referred to a specialist by their PCP," even though "81% of caregivers felt specialist care would be helpful for their child" [3][single-source]. Read together — different cohorts, different states, same direction — under-referral to the guideline-designated specialist tier is not a single-site finding.

What is already in the room in the primary care visit itself

A pre-post quality-improvement chart review at a single New Jersey pediatric primary care practice (41 patients pre-, 38 post-implementation of provider education and a practice guideline toolkit) measured baseline documentation rates for the guideline's own key elements: at baseline, asthma control was assessed/documented in 4.9% of visits, an asthma action plan was documented in 4.9%, and follow-up visits were documented as completed in 48.8% — each of which rose after the education/toolkit intervention (to 39.5%, 28.9%, and 76.3% respectively) [4][single-source]. This is one practice's chart-review baseline, not a national figure, but it is a directly-measured floor on how completely the guideline pathway above is actually followed in routine primary care before an intervention, rather than an assumption about it.

Instrumenting the pathway: EHR-integrated home spirometry has already been piloted

The room a home-monitoring device would need to fit into already has an EHR and, in at least one academic health system, an EHR-embedded clinical decision-support layer. A Mayo Clinic-sponsored protocol describes exactly this integration: a machine-learning/NLP clinical decision support system ("A-GPS") that "automatically extracts and synthesizes pertinent patient data from EHRs for asthma management," enhanced with "real-time patient data... from a home spirometry device and mobile app system (AsthmaTuner)" that "remotely collected patient-reported outcomes for asthma control and lung function and delivered a clinician-prescribed Asthma Action Plan from EHR to patients" [5][single-source · sponsor-reported]. The associated registered trial (NCT06062433, 22 clinician-patient dyads at two Mayo Clinic sites, ages 6–17, parallel-group pragmatic RCT) has since completed with posted results (status COMPLETED, enrollment 49 actual, hasResults=true); its own protocol paper reports the feasibility conclusion — "The technological integration and application of the integrated A-GPS and AsthmaTuner in primary care as a clinical CDS for remote asthma management was feasible" [5][single-source · sponsor-reported] — but this report did not retrieve the posted numeric results themselves (see §5). Notably, the trial's own clinician-eligibility criterion asked participants to "follow recommendations to schedule/see participant and their caregiver for regular asthma follow-up care every 3-6 months" [6][single-source · sponsor-reported] — inside, but at the wide end of, EPR-3's own 1–6-month control-monitoring window [1][single-source].

4. Sources

[1] Asthma Care Quick Reference: Diagnosing and Managing Asthma, NHLBI's own summary of Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma — National Heart, Lung, and Blood Institute, National Institutes of Health (published 2012-09, summarizing EPR-3 published 2007-11; accessed 2026-09-01). DOI 10.1016/j.jaci.2007.09.043 (EPR-3 Summary Report, PMID 17983880) — https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf [guideline] [2] Associations of rurality, child opportunity, and distance with use of pediatric asthma specialists — The Journal of Allergy and Clinical Immunology (published 2026-05-02; accessed 2026-09-01). PMID 42082023 — https://pubmed.ncbi.nlm.nih.gov/42082023/ [peer-reviewed] [3] Pediatric asthma specialist care utilization among marginalized children with poorly controlled asthma — The Journal of Asthma (published 2026-02; accessed 2026-09-01). PMID 41160475 — https://pubmed.ncbi.nlm.nih.gov/41160475/ [peer-reviewed] [4] Providers' Adherence to Evidence-Based Asthma Guidelines in Pediatric Primary Care — Journal of Pediatric Nursing (published 2021, month not given in the PubMed record; accessed 2026-09-01). PMID 33212342 — https://pubmed.ncbi.nlm.nih.gov/33212342/ [peer-reviewed] [5] Pediatric asthma management via integration of a remote spirometry device into an EHR-based artificial intelligence-powered clinical decision support system: A feasibility pragmatic clinical trial — Contemporary Clinical Trials (published 2026-02; accessed 2026-09-01). PMID 41453519 — https://pubmed.ncbi.nlm.nih.gov/41453519/ [peer-reviewed] [6] A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted EHR Dashboard and Mobile Device Compared With Usual Asthma Care to Treat 6-17 Year Old Patients — ClinicalTrials.gov, sponsor Mayo Clinic (registered 2023, most recent record update 2026-07-22; accessed 2026-09-01). NCT06062433 — https://clinicaltrials.gov/study/NCT06062433 [trial-registry] [7] Comparing a Guideline-Based Mobile Health Intervention Versus Usual Care for High-Risk Adolescents With Asthma: Protocol of a Randomized Controlled Trial — JMIR Research Protocols (published 2025-07-25; accessed 2026-09-01). PMID 40712131 — https://pubmed.ncbi.nlm.nih.gov/40712131/ [peer-reviewed] [8] The Asthma Toolkit Bootcamp to Improve Rural Primary Care for Pediatric Asthma — The Journal of Allergy and Clinical Immunology: In Practice (published 2021-08; accessed 2026-09-01). PMID 33864928 — https://pubmed.ncbi.nlm.nih.gov/33864928/ [peer-reviewed]

5. Sourcing & Gaps

Well established: Nothing in this report rests on ≥2 independent primary sources for the same specific quantity — the two under-referral cohorts ([2], [3]) agree in direction (a minority of guideline-indicated children reach a specialist) but come from different populations, methods and time windows, so each quantity is reported individually with its own marker rather than merged into an unmarked plain-fact line.

Thin: The follow-up-cadence, referral-threshold and self-monitoring lines in §3 all rest on a single document — the guideline itself, not a secondary summary — hence [single-source] on every occurrence of [1]. The New Jersey documentation-rate baseline [4] is one practice's chart review: [single-source]. The A-GPS/AsthmaTuner description and its "feasible" conclusion [5] come from the pilot's own protocol/feasibility paper, i.e. the study reporting on its own device and its own outcome: [single-source · sponsor-reported]. The clinician follow-up-cadence eligibility criterion from NCT06062433 [6] is a registered protocol element from the sponsor's own trial record: [single-source · sponsor-reported]. [7] and [8] are listed as located-but-not-read-past-title leads on mobile-health and rural-toolkit interventions for pediatric asthma primary care; they are cited here only to record that they exist and were not appraised, per the rule that a title is not a finding.

Rescoped from class 3: None in this report. Every line above is either a registry/guideline fact (class 1: the EPR-3 cadence and referral thresholds, the NCT06062433 registry record) or a published measured finding (class 2: the two specialist-utilization cohorts, the chart-review documentation rates). No question about what a clinician or family would do was asked or answered here.

Out of scope: No state Medicaid or non-federal payer care-pathway policy was in scope for this report (that sits in the domain's reimbursement material). GINA (Global Initiative for Asthma) international guidance was not searched — this report is scoped to the US NHLBI/NAEPP framework, which is the guideline named in the domain's own population definition. School-based asthma care (school nurse administration of the action plan) surfaced adjacently in search results ([7], [8] touch rural/mobile-health territory) but was not independently researched as its own care-pathway node.

Not searched vs. not found: The numeric posted results for NCT06062433 (the trial's own primary/secondary outcome values — change in caregiver satisfaction, clinician preparation time, number of on-site visits) were not retrieved this pass — the trials/trial-detail connector surfaced that hasResults=true but returned the protocol-level record, not the posted results tables, and no further fetch of the ClinicalTrials.gov results module was attempted. This is not searched, not not found. A national (rather than two-cohort) estimate of pediatric asthma specialist-referral completion was not searched beyond [2] and [3]. AAP-specific policy statements on office spirometry equipment and staffing in general pediatric practice (as opposed to the EPR-3 guideline's own spirometry-age criterion) were not searched this pass.

[inference] Reading a home-monitoring device as "instrumenting an existing step" rather than "adding a new step" to the pathway is this writer's synthesis of the guideline's own self-monitoring language in [1] ("either symptom or peak flow monitoring") — the guideline does not itself make any claim about a specific device, and no source above states this framing. The further reading that under-referral to specialists (§3, [2], [3]) is relevant to a home-monitoring device's care-pathway fit — because it implies persistent-asthma children above step 2–3 may be managed in primary care for longer than the guideline's own referral threshold recommends, which is exactly where a primary-care-deployed monitoring device would sit — is also this writer's synthesis, not a stated finding in either source.

6. Claim Candidates